MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

2017 International Congress

June 4-8, 2017. Vancouver, BC.

View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Effect of bilateral subthalamic nucleus deep brain stimulation on quality of life in advanced Parkinson’s disease patients

    s. tandra, B. ramavath, r.m. kandadai, r. borgohain (hyderabad, India)

  • Effect of deep brain stimulation of the subthalamic nucleus on cranial tremor in Parkinson’s disease

    L. Cameron, C. Kilbane, A. Shaikh (Cleveland, OH, USA)

  • Effect of deep brain stimulation on visuospatial impairment in Parkinson’s disease

    Y. Okahara, Y. Higuchi, K. Aoyagi, M. Abe, T. Yamamoto, Y. Yamanaka, S. Hirano, Y. Iwadate (Chiba, Japan)

  • Effect of Deutetrabenazine by Body Region Score of the Abnormal Involuntary Movement Scale in Tardive Dyskinesia: ARM-TD and AIM-TD Studies

    H. Fernandez, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, K. Anderson (Cleveland, OH, USA)

  • Effect of Deutetrabenazine on QTcF Interval in the AIM-TD Study: a 12-Week, Phase III, Randomized, Double-Blind, Placebo-Controlled Study

    K. Anderson, D. Stamler, M. Davis, S. Factor, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Washington, DC, USA)

  • Effect of Deutetrabenazine on Quality of Life in Patients With Tardive Dyskinesia in AIM-TD, a 12-Week Double-Blind, Placebo-Controlled Study

    S. Factor, K. Anderson, D. Stamler, M. Davis, R. Hauser, J. Isojärvi, L. Jarskog, J. Jimenez-Shahed, R. Kumar, S. Ochudlo, W. Ondo, H. Fernandez (Atlanta, GA, USA)

  • Effect of Droxidopa Treatment on Fear of Falling in Patients With Neurogenic Orthostatic Hypotension: Clinical Trial and “Real World” Results

    S. Kymes, C. François, G. Peng, G. Rowse, S. Isaacson (Deerfield, IL, USA)

  • Effect of early AbobotulinumtoxinA (Dysport®) use after stroke on the time to reach reinjection criteria: asymptomatic versus symptomatic patients

    R. Rosales, K.J. Goh, W. Kumthornthip, M. Mazlan, L. Abdul Latif, M.M. DeLos Santos, C. Chotiyarnwong, P. Tanvijit, J. Balcaitiene, P. Maisonobe, K.-H. Kong (Manila, Philippines)

  • Effect of food on Opicapone pharmacokinetics and pharmacodynamics

    A. Santos, A. Falcão, J. Ferreira, A. Lees, B. Hernandez, F. Rocha, P. Soares-da-Silva (S. Mamede Coronado, Portugal)

  • Effect of levodopa-carbidopa intestinal gel on dyskinesia: Design of an open-label, randomized multicenter 12-week study in advanced Parkinson’s disease patients

    A. Antonini, W. Poewe, D. Standaert, C. Zadikoff, S. Dubow, L. Bergmann, A. Yegin, C. Hall, W. Robieson, V. Felipe, L. Barbato (Venice, Italy)

  • « Previous Page
  • 1
  • …
  • 47
  • 48
  • 49
  • 50
  • 51
  • …
  • 155
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley